SORMEDICA, UAB - financials and debts

Company age: 29 y. 4 mo.

Update

SORMEDICA - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 4,591,926 10,168,511 4,164,169 4,285,010 4,695,208 6,696,099 2,705,061 3,563,486
Profit before tax 91,020 783,892 10,797 61,250 225,277 97,489 -312,176 -383,257
Net profit 78,203 682,868 5,272 51,056 210,536 80,104 -311,561 -383,257
Equity 663,858 1,346,726 1,351,998 1,403,054 1,254,794 1,283,068 971,507 588,250
Liabilities 7,609,214 2,488,348 2,027,857 1,644,469 2,108,071 1,677,373 927,376 1,252,654
Non-current assets 1,821,655 1,576,735 1,191,619 805,440 103,063 143,749 110,135 91,810
Current assets 6,537,597 2,467,092 2,332,122 2,277,590 3,260,411 2,816,792 1,791,259 1,749,098
Total assets 8,359,252 4,043,827 3,523,741 3,083,030 3,363,474 2,960,541 1,901,394 1,840,908
Taxes paid
STI taxes - - - - - 770,526 61,154 -
Social insurance contributions - - - - - 48,899 64,478 74,726
Financial indicators
Revenue change y/y +85.7% +121.4% -59.0% +2.9% +9.6% +42.6% -59.6% +31.7%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 0.9% 16.9% 0.1% 1.7% 6.3% 2.7% -16.4% -20.8%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 11.8% 50.7% 0.4% 3.6% 16.8% 6.2% -32.1% -65.2%
Profit margin Net profit margin. Shows the overall profitability of the company. 1.7% 6.7% 0.1% 1.2% 4.5% 1.2% -11.5% -10.8%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 2.0% 7.7% 0.3% 1.4% 4.8% 1.5% -11.5% -10.8%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 11.5 1.8 1.5 1.2 1.7 1.3 1.0 2.1
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 274,145 782,193 335,368 418,050 599,391 744,011 263,908 323,953

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

SORMEDICA - Social security debts

From To Debt, €
2025-06-11 2025-06-11 215.32
2025-06-08 2025-06-09 203.03
2025-05-16 2025-06-04 203.03
2025-05-04 2025-05-14 865.93
2025-04-16 2025-05-01 865.93
2025-03-28 2025-04-13 1545.15
2025-03-18 2025-03-27 1485.13
2025-02-18 2025-03-13 2145.13
2025-01-16 2025-02-12 2880.81
2025-01-02 2025-01-13 3545.59
2024-12-22 2024-12-31 3545.59
2024-12-17 2024-12-20 3545.59
2024-11-18 2024-12-11 4209.61
2024-10-16 2024-11-13 4944.48
2024-09-19 2024-10-13 5647.37
2024-09-17 2024-09-18 5555.03
2024-09-11 2024-09-16 461.15
2024-08-19 2024-09-10 6215.15
2024-08-14 2024-08-18 1015.82
2024-07-16 2024-08-13 6875.82
2024-07-12 2024-07-15 1917.08
2024-06-18 2024-07-11 7577.08
2024-06-13 2024-06-17 2618.77
2024-05-16 2024-06-12 6278.77
2024-04-17 2024-05-13 6960.72
2024-04-16 2024-04-16 6941.80
2024-04-12 2024-04-15 1343.16
2024-03-18 2024-04-11 7603.16
2024-03-12 2024-03-17 2396.63
2024-02-19 2024-03-11 8306.63
2024-02-12 2024-02-18 3315.85
2024-01-16 2024-02-11 8975.85
2024-01-15 2024-01-15 4059.35
2024-01-02 2024-01-11 9719.35
2023-12-29 2024-01-01 9612.47
2023-12-18 2023-12-28 9719.35
2023-12-14 2023-12-17 5379.68
2023-11-16 2023-12-13 10379.68
2023-11-14 2023-11-15 6409.65
2023-10-17 2023-11-13 11069.65
2023-10-12 2023-10-16 7418.36
2023-09-18 2023-10-11 11758.36
2023-09-13 2023-09-17 7817.10
2023-08-17 2023-09-12 12427.10
2023-08-14 2023-08-16 8289.03
2023-07-18 2023-08-13 13149.03
2023-07-13 2023-07-17 9198.99
2023-06-16 2023-07-12 13858.99
2023-06-13 2023-06-15 9924.60
2023-05-16 2023-06-12 14519.60
2023-05-11 2023-05-15 9933.63
2023-05-02 2023-05-10 15193.63
2023-04-18 2023-04-28 15193.63
2023-04-13 2023-04-17 11238.81
2023-03-16 2023-04-12 15898.81
2023-03-14 2023-03-15 11957.61
2023-02-17 2023-03-13 16567.61
2023-02-14 2023-02-16 13098.89
2023-02-06 2023-02-13 17258.89
2023-01-17 2023-02-03 17258.89
2023-01-13 2023-01-16 14129.85
2022-12-16 2023-01-12 18089.85
2022-12-14 2022-12-15 15005.59
2022-11-21 2022-12-13 18765.59
2022-11-17 2022-11-18 18765.59
2022-11-11 2022-11-16 15499.58
2022-10-18 2022-11-10 19429.58
2022-10-13 2022-10-17 16318.13
2022-09-16 2022-10-12 20128.13
2022-09-14 2022-09-15 16935.48
2022-08-23 2022-09-13 20795.48
2022-08-12 2022-08-22 17661.17
2022-07-18 2022-08-11 21471.17
2022-07-14 2022-07-17 18162.79
2022-06-16 2022-07-13 22172.79
2022-06-14 2022-06-15 19103.80
2022-05-17 2022-06-13 22833.80
2022-05-12 2022-05-16 19378.43
2022-04-19 2022-05-11 23525.78
2022-04-14 2022-04-18 20434.65
2022-03-16 2022-04-13 24594.65
2022-03-14 2022-03-15 21631.61
2022-02-28 2022-03-13 25254.65
2022-02-17 2022-02-27 25242.61
2022-02-14 2022-02-16 22660.28
2022-02-04 2022-02-13 25920.28
2022-01-18 2022-02-03 25918.57
2022-01-14 2022-01-17 21701.41
2021-12-16 2022-01-13 26521.41
2021-12-13 2021-12-15 23849.68
2021-11-16 2021-12-12 27189.68
2021-11-15 2021-11-15 21933.81
2021-10-18 2021-11-14 27859.62
2021-10-14 2021-10-17 21223.59
2021-09-16 2021-10-13 28583.59

SORMEDICA - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
SORMEDICA, UAB (code 123961895) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €3.56M, up 31.7% year on year from €2.71M in 2024, but still 46.8% below the 2023 level of €6.70M. The business remained loss-making, with net loss widening to €383.3K in 2025 from €311.6K in 2024, after a net profit of €80.1K in 2023. Profit margin stood at -10.8% in 2025 versus 1.2% in 2023. Over the three-year period, the revenue base contracted sharply from 2023 to 2024 and then partially recovered in 2025, while profitability deteriorated further. As of 2025, total assets were €1.84M, equity €588.2K and liabilities €1.25M. The equity ratio was 31.9% and debt-to-equity 2.13. Asset turnover was 1.94x. Revenue per employee reached €324.0K, while profit per employee was -€34.8K.